Clinical Profile and Mutations Associated with Multiple Endocrine Neoplasia-Type1 (MEN1) and Their First-Degree Relatives at Risk of Developing MEN1: A Prospective Study

Abstract

Multiple Endocrine Neoplasia type-1 (MEN1) is an autosomal dominant disorder with a combined occurrence of tumours of parathyroid glands, pancreatic islets, and anterior pituitary. About 90% of these patients carry mutations in the MEN1 gene, though the spectrum is not well defined in India. Forty clinically suspected cases of MEN1 were enrolled prospectively over six years; 32 patients (23 index-cases and nine affected relatives) with≥2 classical endocrine tumours of MEN1 were considered definite, and eight were categorised as ‘MEN1-like’. Details of their clinical presentation, treatment and mutational analysis including MEN1 gene, 3′ and 5′ untranslated regions (UTR) of MEN1, CDKN1B, and CaSR genes were collated. Asymptomatic first-degree relatives were also screened. Among the 32 definite MEN1 patients, all had primary hyperparathyroidism, 22 (68.7%) had gastroentero-pancreatic neuroendocrine tumours, and 21 (66%) had pituitary adenoma. Of the 23 definite index-cases, 13 (56.5%) carried mutations in the MEN1 gene. Five of nine affected first-degree relatives (55.5%), and four of 10 asymptomatic relatives (40%) also had MEN1 mutations. Seven of 10 MEN1 mutation-negative definite index-cases harboured p.V109G polymorphism in the CDKN1B gene. All eight MEN1-like cases were negative for mutations and large deletions in MEN1, mutations in 3′ and 5′ UTR of MEN1, CaSR and CDKN1B genes. The study has helped to clearly document the pattern of mutations among Indian MEN1 patients. However, the absence of MEN1 mutation in ~44% of cases and the presence of p.V109G polymorphism in CDKN1B gene raise the question whether such polymorphisms could independently contribute to pathogenesis.

Key words

MEN1 - 3′ and 5′ UTR - CDKN1B - CaSR - hyperparathyroidism

Publication History

Article published online:
14 April 2021

• References

• 1 Marini F, Giusti F, Brandi ML. Genetic test in multiple endocrine neoplasia type 1 syndrome: An evolving story. World J Exp Med 2015; 5: 124-129
• 2 Thakker RV, Newey PJ, Walls GV. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
• 3 Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Front Endocrinol (Lausanne) 2019; 10: 339
• 4 Flanagan DE, Armitage M, Clein GP. et al. Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 1996; 45: 117-120
• 5 Falchetti A. Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. F1000 Res 2017; 6: F1000 Faculty Rev-F1000 Faculty R73
• 6 Turner JJ, Christie PT, Pearce SH. et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum Mutat 2010; 31: E1089-E1101
• 7 Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32
• 8 de Laat JM, van Leeuwaarde RS, Valk GD. The Importance of an Early and Accurate MEN1 Diagnosis. Front Endocrinol (Lausanne) 2018; 9: 533
• 9 Katznelson L, Laws Jr. ER, Melmed S. et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 10 Giustina A, Chanson P, Bronstein MD. et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
• 11 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 12 Nieman LK, Biller BM, Findling JW. et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831
• 13 Chanson P, Raverot G, Castinetti F. et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76: 239-247
• 14 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
• 15 Cryer PE, Axelrod L, Grossman AB. et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94: 709-728
• 16 Fendrich V, Langer P, Waldmann J. et al. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 2007; 94: 1331-1341
• 17 Triponez F, Sadowski SM, Pattou F. et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. Ann Surg 2018; 268: 158-164
• 18 Corbo V, Dalai I, Scardoni M. et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010; 17: 771-783
• 19 Tichomirowa MA, Lee M, Barlier A. et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012; 19: 233-241
• 20 Muddana V, Lamb J, Greer JB. et al. Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. World J Gastroenterol 2008; 14: 4486-4491
• 21 Darling TN, Skarulis MC, Steinberg SM. et al. Multiple facial angiofibromas and collagenomas in patients with Multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133: 853-857
• 22 Tonelli F, Marini F, Giusti F. et al Total and Subtotal parathyroidectomy in young patients with Multiple endocrine neoplasia type 1- related primary hyperparathyroidism: Potential post-surgical benefits and complications. Front Endocrinol (Lausanne) 2018; 9: 558
• 23 Sakurai A, Suzuki S, Kosugi S. et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 2012; 76: 533-539
• 24 Giraud S, Zhang CX, Serova-Sinilnikova O. et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998; 63: 455-467
• 25 Cardinal JW, Bergman L, Hayward N. et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet 2005; 42: 69-74
• 26 Tham E, Grandell U, Lindgren E. et al Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 2007; 92: 3389-3395
• 27 Goroshi M, Bandgar T, Lila AR. et al. Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India. Fam Cancer 2016; 15: 617-624
• 28 Pieterman CR, van Hulsteijn LT, den Heijer M. et al. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg 2012; 255: 1171-1178
• 29 Montenegro FL, Lourenço Jr DM, Tavares MR. et al. Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center. Clinics (Sao Paulo) 2012; 67: 131-139
• 30 Trouillas J, Labat-Moleur F, Sturm N. et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008; 32: 534-543
• 31 Shao QQ, Zhao BB, Dong LB. et al. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25: 4673-4681
• 32 Tonelli F, Giudici F, Nesi G. et al. Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate. Surgery 2017; 161: 727-734
• 33 Challis BG, Casey RT, Grossman A. et al. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?. Clin Endocrinol (Oxf) 2019; 91: 708-715
• 34 Lastoria S, Marciello F, Faggiano A. et al. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine 2016; 52: 488-494
• 35 Ellard S, Hattersley AT, Brewer CM. et al. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 2005; 62: 169-175
• 36 Jäger AC, Friis-Hansen L, Hansen TV. et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Mol Cell Endocrinol 2006; 249: 123-132
• 37 Backman S, Bajic D, Crona J. et al. Whole genome sequencing of apparently mutation-negative MEN1 patients. Eur J Endocrinol 2020; 182: 35-45
• 38 Falchetti A, Marini F, Luzi E. et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med 2009; 11: 825-835
• 39 de Laat JM, van der Luijt RB, Pieterman CR. et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med 2016; 14: 182
• 40 Falchetti A. Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how. F1000 Med Rep 2010; 2: 14
• 41 Marini F, Giusti F, Brandi ML. Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients. Orphanet J Rare Dis 2018; 13: 205
• 42 Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states [published correction appearead in]. J Clin Endocrinol Metab 2009; 94: 2674
• 43 Longuini VC, Lourenço Jr. DM, Sekiya T. et al. Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations. Eur J Endocrinol 2014; 171: 335-342
• 44 Circelli L, Ramundo V, Marotta V. et al. Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1. J Cell Mol Med 2015; 19: 1735-1741
• 45 Wei F, Xu J, Tang L. et al. p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. Cancer Biother Radiopharm 2012; 27: 665-671
• 46 Carvalho RA, Urtremari B, Jorge AAL. et al. Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencing. Eur J Endocrinol 2018; 179: 391-407
• 47 Turner JJ, Leotlela PD, Pannett AA. et al. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2002; 87: 2688-2693